Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
Cancer
    May 2024
  1. NING T, Li D, Deng T, Bai Y, et al
    Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
    Cancer. 2024 May 23. doi: 10.1002/cncr.35377.
    >> Share

  2. NIERENGARTEN MB
    Global phase 3 results show that bevacizumab with immunotherapy has activity in liver cancer.
    Cancer. 2024;130:1547-1548.
    >> Share

    February 2024
  3. CONNOLLY GK, Harris RD, Shumate C, Rednam SP, et al
    Pediatric cancer incidence among individuals with overgrowth syndromes and overgrowth features: A population-based assessment in seven million children.
    Cancer. 2024;130:467-475.
    >> Share

    January 2024
  4. PORTA C, Negri F, Cosmai L
    Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expected.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35218.
    >> Share

  5. PISCAGLIA F, Ikeda K, Cheng AL, Kudo M, et al
    Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
    Cancer. 2024 Jan 23. doi: 10.1002/cncr.35185.
    >> Share

  6. COLLOCA GA, Venturino A
    Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial-level analysis.
    Cancer. 2024 Jan 17. doi: 10.1002/cncr.35199.
    >> Share

    November 2023
  7. ACUNA N, Zhou K, Pinheiro PS, Cheng I, et al
    Increasing risk of hepatocellular carcinoma with successive generations in the United States among Mexican American adults: The Multiethnic Cohort.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35000.
    >> Share

  8. WONG EC, Lupo PJ, Desrosiers TA, Nichols HB, et al
    Associations between birth defects with neural crest cell origins and pediatric embryonal tumors.
    Cancer. 2023;129:3595-3602.
    >> Share


  9. Erratum to "Association between posttreatment alpha-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma".
    Cancer. 2023 Nov 4. doi: 10.1002/cncr.35102.
    >> Share

    October 2023
  10. HALLEMEIER CL, Sharma N, Anker C, Selfridge JE, et al
    American Radium Society Appropriate Use Criteria for the use of liver-directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines.
    Cancer. 2023;129:3193-3212.
    >> Share

    August 2023

  11. Erratum to "Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013".
    Cancer. 2023 Aug 1. doi: 10.1002/cncr.34961.
    >> Share

    July 2023
  12. BUSH DA, Volk M, Smith JC, Reeves ME, et al
    Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial.
    Cancer. 2023 Jul 28. doi: 10.1002/cncr.34965.
    >> Share

  13. CAI QY, Yang P, Yang XL, Zhang XH, et al
    The association of carbohydrate antigen 19-9 response with radiologic response and survival in intrahepatic cholangiocarcinoma: A prospective cohort study.
    Cancer. 2023 Jul 14. doi: 10.1002/cncr.34854.
    >> Share

  14. CHEN Q, Wang X, Zheng Y, Ye T, et al
    Cancer-associated fibroblasts contribute to the immunosuppressive landscape and influence the efficacy of the combination therapy of PD-1 inhibitors and antiangiogenic agents in hepatocellular carcinoma.
    Cancer. 2023 Jul 3. doi: 10.1002/cncr.34935.
    >> Share

    May 2023
  15. BAEK GT, Huang IJ, Gopal AK
    Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
    Cancer. 2023 May 19. doi: 10.1002/cncr.34816.
    >> Share

    April 2023
  16. JENG LB, Li TC, Wang J, Teng CF, et al
    Increased plasma levels of monocyte chemoattractant protein-1 in patients with hepatitis B virus pre-S2 gene deletion mutation predict a higher risk of hepatocellular carcinoma recurrence after curative surgical resection.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34815.
    >> Share

  17. YU YC, Paragomi P, Wang R, Liang F, et al
    High serum magnesium is associated with lower risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease.
    Cancer. 2023 Apr 13. doi: 10.1002/cncr.34799.
    >> Share

  18. AN C, Fu Y, Li W, Zuo M, et al
    Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to HAIC.
    Cancer. 2023 Apr 7. doi: 10.1002/cncr.34764.
    >> Share

    March 2023
  19. ABOU-ALFA GK, Wang X, Parrinello CM, Gossai A, et al
    Association between posttreatment alpha-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma.
    Cancer. 2023 Mar 21. doi: 10.1002/cncr.34754.
    >> Share

  20. ORIGA R, Gianesin B, Longo F, Di Maggio R, et al
    Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies".
    Cancer. 2023 Mar 14. doi: 10.1002/cncr.34736.
    >> Share

  21. MANCUSO A, Butera G, Rossi M, Maringhini A, et al
    Hepatocellular carcinoma in thalassemia and other hemoglobinopathies.
    Cancer. 2023 Mar 14. doi: 10.1002/cncr.34735.
    >> Share

    January 2023
  22. COFFMAN-D'ANNIBALE KL, Greten TF
    Top advances of the year: Hepatobiliary cancers.
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34652.
    >> Share

  23. ZHANG J, Huang Q, Yang Y, Zhang J, et al
    A novel prognostic system combining carbonic anhydrase II and preoperative CA19-9 for intrahepatic cholangiocarcinoma after curative resection.
    Cancer. 2023 Jan 10. doi: 10.1002/cncr.34639.
    >> Share

  24. ORIGA R, Gianesin B, Longo F, Di Maggio R, et al
    Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021.
    Cancer. 2023;129:107-117.
    >> Share

    December 2022
  25. FU Y, Li X, Yang Z, Li S, et al
    A risk-based post-resection follow-up strategy for hepatocellular carcinoma patients.
    Cancer. 2022 Dec 20. doi: 10.1002/cncr.34601.
    >> Share


  26. New assay for early detection of hepatocellular carcinoma.
    Cancer. 2022;128:4176.
    >> Share

    November 2022
  27. ZHENG Y, Huang N, Kuang S, Zhang J, et al
    The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery.
    Cancer. 2022 Nov 26. doi: 10.1002/cncr.34552.
    >> Share

  28. NAKAGAWA M, Inoue M, Ogasawara S, Maruta S, et al
    Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
    Cancer. 2022 Nov 24. doi: 10.1002/cncr.34559.
    >> Share

  29. NIERENGARTEN MB
    Blood-based test to predict future risk of developing liver cancer: Researchers recently discovered a genetic signature that can help predict long-term hepatocellular carcinoma risk in patients who have nonalcoholic fatty liver disease, and may also h
    Cancer. 2022;128:3904.
    >> Share

    October 2022
  30. CAO M, Li H, Sun D, He S, et al
    Assessment of the compliance, influencing factors, and yielding results of liver cancer screening in a high-risk population: A cross-sectional study.
    Cancer. 2022;128:3653-3662.
    >> Share

    September 2022
  31. LI Y, Liang X, Li H, Chen X, et al
    Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Cancer. 2022 Sep 16. doi: 10.1002/cncr.34457.
    >> Share

  32. MATTINGLY TJ 2ND, Shetty K
    The economics of advanced and unresectable hepatocellular carcinoma.
    Cancer. 2022 Sep 15. doi: 10.1002/cncr.34456.
    >> Share

    August 2022
  33. LEE YT, Singal AG, Lauzon M, Agopian VG, et al
    Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.
    Cancer. 2022 Aug 23. doi: 10.1002/cncr.34436.
    >> Share

  34. JALAL PK
    Hepatitis C infection and advanced hepatocellular carcinoma-To treat or not to treat?
    Cancer. 2022 Aug 9. doi: 10.1002/cncr.34408.
    >> Share

    July 2022
  35. PARIKH ND, Mehta N, Hoteit MA, Yang JD, et al
    Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma.
    Cancer. 2022 Jul 7. doi: 10.1002/cncr.34378.
    >> Share

    May 2022
  36. SHORT SS, Kastenberg ZJ, Wei G, Bondoc A, et al
    Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study.
    Cancer. 2022 May 13. doi: 10.1002/cncr.34256.
    >> Share

    April 2022
  37. DE B, Tran Cao HS, Vauthey JN, Manzar GS, et al
    Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States.
    Cancer. 2022 Apr 13. doi: 10.1002/cncr.34223.
    >> Share

    March 2022
  38. LEBECK LEE CM, Ziogas IA, Agarwal R, Alexopoulos SP, et al
    A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer.
    Cancer. 2022 Mar 14. doi: 10.1002/cncr.34170.
    >> Share

  39. ROBERTS HJ, Wo JY
    Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox.
    Cancer. 2022;128:956-965.
    >> Share

    January 2022
  40. NIERENGARTEN MB
    Aspirin decreases the risk of hepatocellular cancer in at-risk patients.
    Cancer. 2022;128:214-215.
    >> Share

    November 2021
  41. KATZENSTEIN HM, Malogolowkin MH, Krailo MD, Piao J, et al
    Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.
    Cancer. 2021 Nov 11. doi: 10.1002/cncr.34014.
    >> Share

    October 2021
  42. DUONG LM, Cai H, Shrubsole MJ, Bailey CE, et al
    Outcomes of robotic-assisted liver surgery versus laparoscopic liver surgery for treatment of stage I hepatocellular carcinoma.
    Cancer. 2021 Oct 21. doi: 10.1002/cncr.33979.
    >> Share

  43. CHENG K, Chen Y, Wang X, Xu M, et al
    Entecavir combined with interferon-alpha is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B.
    Cancer. 2021 Oct 8. doi: 10.1002/cncr.33949.
    >> Share

    August 2021
  44. HARDING JJ, Yang TS, Chen YY, Feng YH, et al
    Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
    Cancer. 2021 Aug 20. doi: 10.1002/cncr.33870.
    >> Share

    July 2021
  45. MERRIAM P, Nathenson MJ
    Liver transplantation for hepatic epithelioid hemangioendothelioma.
    Cancer. 2021 Jul 13. doi: 10.1002/cncr.33751.
    >> Share

  46. DING X, Sun W, Li W, Shen Y, et al
    Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Cancer. 2021 Jul 8. doi: 10.1002/cncr.33677.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016